iPierian to Collaborate With Johns Hopkins University on $3.7 Million NIH Grant for ALS Research

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University. The grant, given over a two-year span, will be used to generate amyotrophic lateral sclerosis (ALS) iPS cells and to evaluate the ability of these cells to reflect human cell biology and the characteristics of native motor neurons and astrocytes, the cell types involved in ALS. The grant was awarded under the American Recovery and Reinvestment Act of 2009 by the National Institute of Neurological Disorders and Stroke (NINDS) of the NIH.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail